Clinical Trials Logo
  1. Home
  2. Hematopoietic/Lymphoid Cancer
  3. NCT04138875

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Hematopoietic/Lymphoid Cancer Clinical Trial

Official title:
A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.

Clinical Trial Summary

This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression. It includes an induction phase with rituximab and brentuximab vedotin (RBv), followed by a treatment phase with RBv or RBv in combination with bendamustine (RBvB) based on response to induction. The primary end point is treatment efficacy measured as the overall response rate (ORR) and progression free survival (PFS).

Clinical Trial Description

Post-Transplant Lymphoproliferative Disorders (PTLD) are defined by the revised 2017 edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues as "lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in a recipient of a solid organ, bone marrow or stem cell allograft". Within this definition 4 distinct categories exist, including: (1) Non-destructive PTLDs (plasmacytic hyperplasia, infectious mononucleosis, and florid follicular hyperplasia) (2) Polymorphic PTLD; (3) Monomorphic PTLD and (4) Classical Hodgkin Lymphoma type PTLD. The incidence of PTLD varies between different transplanted organs. Across all transplants monomorphic PTLD is the most common accounting for 75% of all cases. Lymphoma derived of B- cell origin account for the majority of cases (70%), while T-cell neoplasms represent a small minority (5%). Within monomorphic PTLD 50% of cases demonstrate association with the Epstein Barr Virus (EBV). Polymorphic PTLD accounts for 15-20% of all PTLD cases with the majority demonstrating EBV involvement. Early lesions account for 5% of PTLD and are all uniformly associated with EBV as are all the cases of Classic Hodgkin Lymphoma type PTLD. The current understanding of the pathogenesis of PTLD is incomplete. Despite concerted efforts, the investigators are unable to predict who will develop PTLD and do not understand why only 1 - 2% of all transplant recipients develop these disorders. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04138875
Study type Interventional
Source Yale University
Contact
Status Withdrawn
Phase Phase 2
Start date January 2022
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02903810 - Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy Phase 1/Phase 2
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Active, not recruiting NCT01056614 - Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies Phase 2
Terminated NCT00089089 - Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Completed NCT01212380 - Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) Phase 1
Completed NCT00896792 - Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers Early Phase 1
Recruiting NCT03110640 - Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma Phase 1
Completed NCT01982682 - Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Phase 2
Completed NCT00833898 - Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT) Phase 3
Active, not recruiting NCT05147311 - Positive Psychology Intervention In HSCT N/A
Completed NCT04172818 - Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families N/A
Completed NCT00670917 - Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy N/A
Withdrawn NCT00899808 - Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer N/A
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Completed NCT02194413 - Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant N/A
Completed NCT01029366 - CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy Phase 1
Terminated NCT03121534 - Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation Phase 2
Withdrawn NCT01620229 - Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT01866969 - Quality of Life in Caregivers of Hospitalized Older Patients With Cancer N/A